Log in to search using one of your social media accounts:


A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blockade of inhibitory killer-cell immunoglobulin receptor (KIR) receptors induces augmented NK-cell mediated tumor cell lysis (Romagne F et al., Blood 2009). Hypomethylating agents (HMAs) possess anti-leukemia activity, and increase MHC II expression, cancer antigen exposure in solid and hematologic malignancies, and interferon-gamma signature. KIR-receptor blockade by lirilumab (KIR2DL1/2/3-antibody) may improve responses to HMAs.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Study